Proven


Protection

Only ALECENSA 1L is proven to deliver 

nearly 3 years free from PROGRESSION IN 

ALK+ ADVANCED NSCLC1

ALEX Phase III trial: PFS analysis1

Nearly

3 YEARS
mPFS1

Efficacy that lasts for years
regardless of baseline CNS metastases1

ALEX Phase III trial: mPFS of patients with pre-existing CNS metastases1

>2 YEARS
mPFS1

 

 

ALEX Phase III trial: mPFS of patients without pre-existing CNS metastases1

>3 YEARS
mPFS1

ALECENSA 1L reduces the risk
of CNS progression2,*

ALEX Phase III trial: cumulative incidence of CNS progression (ITT population)2

84%

Reduction
vs crizotinib2

Discover

 

How ALECENSA PROVIDES

SUPERIOR SURVIVAL >

*At 1 year. †Cause-specific HR; adjusted for competing risk of non-CNS progression and death.


1L: first line; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; HR: hazard ratio; ITT: intention-to-treat; mPFS: median progression-free survival; NE: not estimable; NSCLC: non-small cell lung cancer; PFS: progression-free survival; SmPC: Summary of Product Characteristics.


1. Mok T, et al. Ann Oncol 2020;31(8):1056–1064; 2. Peters S, et al. N Engl J Med 2017;377(9):829–838.